Bosh sahifaGRFS • NASDAQ
add
Grifols SA - ADR ADR Class B
7,21 $
Seans yopilganidan keyin:(0,00%)0,00
7,21 $
Yopilgan:25-apr, 20:00:00 (GMT-4) · USD · NASDAQ · Ogohlantirish
Yopilish kursi
7,18 $
Kunlik diapazon
7,15 $ - 7,33 $
Yillik diapazon
5,79 $ - 9,96 $
Bozor kapitalizatsiyasi
5,99 mlrd USD
Oʻrtacha hajm
984,18 ming
Yangiliklarda
GRF
0,78%
0,41%
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
(EUR) | dek, 2024info | Y/Y qiyosi |
---|---|---|
Daromad | 1,98 mlrd | 11,66% |
Joriy xarajat | 353,12 mln | 20,32% |
Sof foyda | 68,97 mln | 76,86% |
Sof foyda marjasi | 3,49 | 58,64% |
Har bir ulushga tushum | — | — |
EBITDA | 495,68 mln | -11,49% |
Amaldagi soliq stavkasi | 60,20% | — |
Balans
Jami aktivlari
Jami passivlari
(EUR) | dek, 2024info | Y/Y qiyosi |
---|---|---|
Naqd pul va qisqa investitsiyalar | 1,00 mlrd | 55,40% |
Jami aktivlari | 21,41 mlrd | 1,97% |
Jami passivlari | 12,80 mlrd | -5,05% |
Umumiy kapital | 8,61 mlrd | — |
Tarqatilgan aksiyalar | 680,41 mln | — |
Narxi/balansdagi bahosi | 0,83 | — |
Aktivlardan daromad | 5,08% | — |
Kapitaldan daromad | 5,79% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
(EUR) | dek, 2024info | Y/Y qiyosi |
---|---|---|
Sof foyda | 68,97 mln | 76,86% |
Operatsiyalardan naqd pul | 514,62 mln | 208,54% |
Sarmoyadan naqd pul | -178,31 mln | -28,31% |
Moliyadan naqd pul | -27,16 mln | -185,08% |
Naqd pulning sof oʻzgarishi | 334,84 mln | 658,87% |
Boʻsh pul | 162,44 mln | 123,56% |
Haqida
Grifols, S.A. is a global healthcare company and leading producer of plasma-derived medicines founded in Barcelona, Spain, in 1909. With a workforce of over 23,800 employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over than 30.
Principally a producer of blood plasma–based products, a field in which it is the European leader and third largest worldwide, and other biopharmaceuticals, the company is also in transfusion medicine, supplying devices, instruments and reagents for clinical testing laboratories, in addition to clinical diagnostic technologies. Grifols also provides biological supplies for life-science research, clinical trials and for manufacturing pharmaceutical and diagnostic products.
Grifols is focused on four main therapeutic areas: immunology, infectious diseases, pulmonology and critical care. Wikipedia
CEO
Tashkil etilgan
18-noy, 1940
Sayt
Xodimlar soni
23 833